Skip to content

Zymeworks ZYME Free cash flow yield

Free cash flow yield at other companies

Pfizer logo
PfizerPFE
7.8%+4.6pp
Amgen logo
AmgenAMGN
4.5%-2.0pp
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
0.3%+0.1pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-15.2%-4.4pp
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-17.9%-2.6pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
19.2%+13.6pp

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Calculated from Zymeworks’s reported figures.

Based on trailing twelve months.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's free cash flow yield?
Zymeworks (ZYME) reported free cash flow yield of -4.1% in Q1 2026.
How has Zymeworks's free cash flow yield changed year-over-year?
Zymeworks's free cash flow yield increased by 55.8% year-over-year, from -9.4% to -4.1%.
What is the long-term trend for Zymeworks's free cash flow yield?
Over 3 years (2020 to 2025), Zymeworks's free cash flow yield has grown at a -37.4% compound annual growth rate (CAGR), from -7.1% to -1.7%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.